Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico: controllo del dolore e delle complicanze muscolo-scheletriche.

Translated title of the contribution: [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].

Stefano Paparella, Elisabetta Finkelberg, Daniela Varisco, Elena Tondelli, Francesco Rocco

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Patients suffering from prostatic carcinoma are at high risk of having bone complications because of the metastatic progression of the disease to the skeleton and the consequences of androgenic deprivation. Zoledronic acid is a potent inhibitor of the bone resorption mediated by the osteoclasts, and is the only bisphosphonate whose capacity of reducing significantly the skeleton morbidity in patients with bone metastases is statistically proved. Methods. To attest tolerability and efficacy of zoledronic acid in preventing unfavorable skeletal events and in reducing osteomuscular pain, 25 patients - aged 75 years, suffering from hormone-responsive prostatic carcinoma under hormonal therapy with bone metastases, have been followed and subjected to IV monthly infusion of 4 mg zoledronic acid for 12 consecutive months, associated to daily intake of calcium and multivitamin supplementations. Results. At the end of the study, a sensible improvement in their clinical conditions and in their perception of the pain has been recorded in 23 patients and valued through a set of questions (Brief Pain Inventory). Conclusions. Zoledronic acid is therefore confirmed to be an effective medicine in preventing the skeleton complications and in controlling the painful symptoms in patients suffering from prostatic carcinoma with bone metastases.

Original languageItalian
Pages (from-to)300-304
Number of pages5
JournalUrologia
Volume78
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

zoledronic acid
Musculoskeletal Pain
Bone Neoplasms
Prostatic Neoplasms
Neoplasm Metastasis
Skeleton
Bone and Bones
Carcinoma
Bone Density Conservation Agents
Pain
Pain Perception
Diphosphonates
Osteoclasts
Disease Progression
Medicine
Hormones
Calcium
Morbidity
Equipment and Supplies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico : controllo del dolore e delle complicanze muscolo-scheletriche. / Paparella, Stefano; Finkelberg, Elisabetta; Varisco, Daniela; Tondelli, Elena; Rocco, Francesco.

In: Urologia, Vol. 78, No. 4, 10.2011, p. 300-304.

Research output: Contribution to journalArticle

Paparella, Stefano ; Finkelberg, Elisabetta ; Varisco, Daniela ; Tondelli, Elena ; Rocco, Francesco. / Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico : controllo del dolore e delle complicanze muscolo-scheletriche. In: Urologia. 2011 ; Vol. 78, No. 4. pp. 300-304.
@article{bf141523db9e4444985a09c12a970f41,
title = "Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico: controllo del dolore e delle complicanze muscolo-scheletriche.",
abstract = "Background. Patients suffering from prostatic carcinoma are at high risk of having bone complications because of the metastatic progression of the disease to the skeleton and the consequences of androgenic deprivation. Zoledronic acid is a potent inhibitor of the bone resorption mediated by the osteoclasts, and is the only bisphosphonate whose capacity of reducing significantly the skeleton morbidity in patients with bone metastases is statistically proved. Methods. To attest tolerability and efficacy of zoledronic acid in preventing unfavorable skeletal events and in reducing osteomuscular pain, 25 patients - aged 75 years, suffering from hormone-responsive prostatic carcinoma under hormonal therapy with bone metastases, have been followed and subjected to IV monthly infusion of 4 mg zoledronic acid for 12 consecutive months, associated to daily intake of calcium and multivitamin supplementations. Results. At the end of the study, a sensible improvement in their clinical conditions and in their perception of the pain has been recorded in 23 patients and valued through a set of questions (Brief Pain Inventory). Conclusions. Zoledronic acid is therefore confirmed to be an effective medicine in preventing the skeleton complications and in controlling the painful symptoms in patients suffering from prostatic carcinoma with bone metastases.",
author = "Stefano Paparella and Elisabetta Finkelberg and Daniela Varisco and Elena Tondelli and Francesco Rocco",
year = "2011",
month = "10",
doi = "10.5301/RU.2011.8877",
language = "Italian",
volume = "78",
pages = "300--304",
journal = "Urologia",
issn = "0391-5603",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico

T2 - controllo del dolore e delle complicanze muscolo-scheletriche.

AU - Paparella, Stefano

AU - Finkelberg, Elisabetta

AU - Varisco, Daniela

AU - Tondelli, Elena

AU - Rocco, Francesco

PY - 2011/10

Y1 - 2011/10

N2 - Background. Patients suffering from prostatic carcinoma are at high risk of having bone complications because of the metastatic progression of the disease to the skeleton and the consequences of androgenic deprivation. Zoledronic acid is a potent inhibitor of the bone resorption mediated by the osteoclasts, and is the only bisphosphonate whose capacity of reducing significantly the skeleton morbidity in patients with bone metastases is statistically proved. Methods. To attest tolerability and efficacy of zoledronic acid in preventing unfavorable skeletal events and in reducing osteomuscular pain, 25 patients - aged 75 years, suffering from hormone-responsive prostatic carcinoma under hormonal therapy with bone metastases, have been followed and subjected to IV monthly infusion of 4 mg zoledronic acid for 12 consecutive months, associated to daily intake of calcium and multivitamin supplementations. Results. At the end of the study, a sensible improvement in their clinical conditions and in their perception of the pain has been recorded in 23 patients and valued through a set of questions (Brief Pain Inventory). Conclusions. Zoledronic acid is therefore confirmed to be an effective medicine in preventing the skeleton complications and in controlling the painful symptoms in patients suffering from prostatic carcinoma with bone metastases.

AB - Background. Patients suffering from prostatic carcinoma are at high risk of having bone complications because of the metastatic progression of the disease to the skeleton and the consequences of androgenic deprivation. Zoledronic acid is a potent inhibitor of the bone resorption mediated by the osteoclasts, and is the only bisphosphonate whose capacity of reducing significantly the skeleton morbidity in patients with bone metastases is statistically proved. Methods. To attest tolerability and efficacy of zoledronic acid in preventing unfavorable skeletal events and in reducing osteomuscular pain, 25 patients - aged 75 years, suffering from hormone-responsive prostatic carcinoma under hormonal therapy with bone metastases, have been followed and subjected to IV monthly infusion of 4 mg zoledronic acid for 12 consecutive months, associated to daily intake of calcium and multivitamin supplementations. Results. At the end of the study, a sensible improvement in their clinical conditions and in their perception of the pain has been recorded in 23 patients and valued through a set of questions (Brief Pain Inventory). Conclusions. Zoledronic acid is therefore confirmed to be an effective medicine in preventing the skeleton complications and in controlling the painful symptoms in patients suffering from prostatic carcinoma with bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=84861179162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861179162&partnerID=8YFLogxK

U2 - 10.5301/RU.2011.8877

DO - 10.5301/RU.2011.8877

M3 - Articolo

C2 - 22139807

AN - SCOPUS:84861179162

VL - 78

SP - 300

EP - 304

JO - Urologia

JF - Urologia

SN - 0391-5603

IS - 4

ER -